There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer
The hype around hyperthermic intraperitoneal chemotherapy (HIPEC) started two decades ago when a randomized trial comparing surgery and HIPEC against palliative chemotherapy only in patients with colorectal cancer showed favorable results. In ovarian cancer, data from three prospective randomized co...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/123856 |
| Acceso en línea: | https://hdl.handle.net/10171/123856 |
| Access Level: | acceso abierto |
| Palabra clave: | Cystadenocarcinoma Cytoreduction surgical procedures General surgery Operative Ovarian cancer Serous Surgical procedures |
| Sumario: | The hype around hyperthermic intraperitoneal chemotherapy (HIPEC) started two decades ago when a randomized trial comparing surgery and HIPEC against palliative chemotherapy only in patients with colorectal cancer showed favorable results. In ovarian cancer, data from three prospective randomized controlled trials and several retrospective trials are available. |
|---|